Faculty Opinions recommendation of Mortality risk of darbepoetin alfa versus epoetin alfa in patients with CKD: systematic review and meta-analysis.

Several retrospectivee described the association of interstitial lung disease (ILD) and ANCA-associated vasculitis (AAV). However, the relationship between the ILD and mortality in AAV patients have not been established so far. This study aims to estimate the relevance of AAV-associated-ILD (AAV-ILD) and mortality risk by conducting a systematic review and meta-analysis.A comprehensive systematic review was conducted in accordance with the guidelines of PRISMA (Preferred Reporting Items for Systematic Reviews and Meta-analyses). PubMed, Embase.com and the Cochrane Library (Wiley) were searched for original observational studies. Summary estimates were derived with a random-effects model and reported as risk ratio (RR), tested for publication bias and heterogeneity. Ten retrospective cohort studies were included, comprising 526 AAV-ILD patients enrolled from 1974 to 2018. Meta-analysis yielded a pooled RR of 2.90 (95% confidence interval 1.77–4.74) for death among those with AAV-ILD compared to control group. UIP pattern was associated with an even poorer prognosis in comparison to non-UIP pattern (RR 4.36, 95% confidence interval 1.14–16.78). Sensitivity analysis suggested that the meta-RR result was not skewed by a single dominant study. ILD might be associated with a higher mortality risk in AAV patients.

Download Full-text

CARDIOVASCULAR MORTALITY RISK IN PATIENTS WITH PROSTATE CANCER TREATED WITH ANDROGEN DEPRIVATION THERAPY: A SYSTEMATIC REVIEW AND META-ANALYSIS

Journal of the American College of Cardiology ◽

10.1016/s0735-1097(20)30875-5 ◽

2020 ◽

Vol 75 (11) ◽

pp. 248

Author(s):

Neville Tan ◽

Christopher Neil ◽

Nicholas Cox ◽

Mark Nolan

Keyword(s):

Prostate Cancer ◽

Systematic Review ◽

Androgen Deprivation Therapy ◽

Mortality Risk ◽

Cardiovascular Mortality ◽

Meta Analysis ◽

Androgen Deprivation ◽

Cardiovascular Mortality Risk

Download Full-text

Impact of cardiovascular disease and cardiac injury on in-hospital mortality in patients with COVID-19: a systematic review and meta-analysis

Heart ◽

10.1136/heartjnl-2020-317062 ◽

2020 ◽

Vol 106 (15) ◽

pp. 1142-1147 ◽

Cited By ~ 25

Author(s):

Xintao Li ◽

Bo Guan ◽

Tong Su ◽

Wei Liu ◽

Mengyao Chen ◽

...

Keyword(s):

Systematic Review ◽

Cardiovascular Disease ◽

Hospital Mortality ◽

Mortality Risk ◽

Meta Analysis ◽

Cardiac Injury ◽

Sensitivity Analyses ◽

Future Research ◽

Cardiovascular Comorbidities ◽

The Impact

BackgroundCoronavirus disease 2019 (COVID-19) has produced a significant health burden worldwide, especially in patients with cardiovascular comorbidities. The aim of this systematic review and meta-analysis was to assess the impact of underlying cardiovascular comorbidities and acute cardiac injury on in-hospital mortality risk.MethodsPubMed, Embase and Web of Science were searched for publications that reported the relationship of underlying cardiovascular disease (CVD), hypertension and myocardial injury with in-hospital fatal outcomes in patients with COVID-19. The ORs were extracted and pooled. Subgroup and sensitivity analyses were performed to explore the potential sources of heterogeneity.ResultsA total of 10 studies were enrolled in this meta-analysis, including eight studies for CVD, seven for hypertension and eight for acute cardiac injury. The presence of CVD and hypertension was associated with higher odds of in-hospital mortality (unadjusted OR 4.85, 95% CI 3.07 to 7.70; I2=29%; unadjusted OR 3.67, 95% CI 2.31 to 5.83; I2=57%, respectively). Acute cardiac injury was also associated with a higher unadjusted odds of 21.15 (95% CI 10.19 to 43.94; I2=71%).ConclusionCOVID-19 patients with underlying cardiovascular comorbidities, including CVD and hypertension, may face a greater risk of fatal outcomes. Acute cardiac injury may act as a marker of mortality risk. Given the unadjusted results of our meta-analysis, future research are warranted.

Download Full-text

Analysis of neonatal mortality risk factors in Brazil: a systematic review and meta-analysis of observational studies

Jornal de Pediatria ◽

10.1016/j.jped.2018.12.014 ◽

2019 ◽

Vol 95 (5) ◽

pp. 519-530 ◽

Cited By ~ 1

Author(s):

Felipe Camilo Santiago Veloso ◽

Liliana de Meira Lins Kassar ◽

Michelle Jacintha Cavalcante Oliveira ◽

Telmo Henrique Barbosa de Lima ◽

Nassib Bezerra Bueno ◽

...

Keyword(s):

Risk Factors ◽

Systematic Review ◽

Neonatal Mortality ◽

Mortality Risk ◽

Observational Studies ◽

Meta Analysis

Download Full-text

Warfarin use and stroke, bleeding and mortality risk in patients with end stage renal disease and atrial fibrillation: a systematic review and meta-analysis

BMC Nephrology ◽

10.1186/s12882-016-0368-6 ◽

2016 ◽

Vol 17 (1) ◽

Cited By ~ 46

Author(s):

Jingwen Tan ◽

Shuiqing Liu ◽

Jodi B. Segal ◽

G. Caleb Alexander ◽

Mara McAdams-DeMarco

Keyword(s):

Atrial Fibrillation ◽

Systematic Review ◽

Renal Disease ◽

Mortality Risk ◽

End Stage Renal Disease ◽

Meta Analysis ◽

Stage Renal Disease ◽

End Stage

Download Full-text

Hypoxaemia as a Mortality Risk Factor in Acute Lower Respiratory Infections in Children in Low and Middle-Income Countries: Systematic Review and Meta-Analysis

PLoS ONE ◽

10.1371/journal.pone.0136166 ◽

2015 ◽

Vol 10 (9) ◽

pp. e0136166 ◽

Cited By ~ 42

Author(s):

Marzia Lazzerini ◽

Michela Sonego ◽

Maria Chiara Pellegrin

Keyword(s):

Systematic Review ◽

Risk Factor ◽

Mortality Risk ◽

Respiratory Infections ◽

Meta Analysis ◽

Middle Income ◽

Middle Income Countries ◽

Acute Lower Respiratory Infections ◽

Low And Middle Income

Download Full-text

Meta-analysis of the effects on safety of front-loading (FL), every-2-week (Q2W), and Q3W dosing of darbepoetin alfa (DA) in patients (pts) with chemotherapy-induced anemia (CIA).

Journal of Clinical Oncology ◽

10.1200/jco.2012.30.15_suppl.e19511 ◽

2012 ◽

Vol 30 (15_suppl) ◽

pp. e19511-e19511

Author(s):

John A. Glaspy ◽

Dusan Kotasek ◽

Jean-Luc Canon ◽

Dianne Tomita ◽

Helen Collins ◽

...

Keyword(s):

Adverse Events ◽

Active Control ◽

Random Effects ◽

Darbepoetin Alfa ◽

Comparison Group ◽

Meta Analysis ◽

Rapid Rate ◽

Thromboembolic Events ◽

Epoetin Alfa ◽

Safety Risks

e19511 Background: Several studies evaluated if alternate dosing could decrease the time to hemoglobin (Hb) response. With recent safety concerns, this is now of limited interest; however, these studies may contribute to the understanding of safety risks. This study-level meta-analysis examined effects of FL, Q2W, and Q3W dosing of DA vs epoetin alfa (EA) and weekly DA dosing on safety in pts with CIA. Methods: Data from 11 studies (4 FL, 5 Q2W, 1 Q3W, 1 Q2W/Q3W) conducted between 1999 and 2006 in which the comparison group received 3-times-per-week (TIW) or once-weekly (QW) EA or QW DA were included in the meta-analysis. FL dosing differed between the studies and was defined as DA 4.5 mcg/kg or 300 mg QW for 4 or 5 weeks or until Hb > 12 g/dL followed by either DA 4.5 mcg/kg Q3W or a lower QW dose. Endpoints included deaths on study; disease progression (PD); embolic, thrombotic, and thromboembolic events; and rapid Hb rise (1 g/dL within 14 days). Random effects odds ratios (ORs) are provided comparing FL, Q2W, or Q3W arms to either TIW or QW active control arms. Heterogeneity was assessed using I2 statistic. Results: No differences in ORs for death, PD, embolic, thrombotic, and thromboembolic events or evidence of a more rapid rate of Hb rise were observed in FL, Q2W, and Q3W arms compared with controls (table). Conclusions: Results of this meta-analysis suggested that these adverse events were not related to FL, Q2W, or Q3W dosing of DA. [Table: see text]

Download Full-text